Maria C. Bell

Maria C. Bell

Oncology

414 N. 7th St.
Bismarck, ND 58501

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal: JCO precision oncology

Published: July 15, 2026

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal: JCO precision oncology

Published: April 30, 2026

Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].

Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].

Journal: Gynecologic oncology

Published: November 07, 2025

Recapitulating physiologically relevant oxygen levels and extracellular matrix remodeling in patient-derived tumor-immune tunable models reveal targeting opportunities for immunologically cold high-grade serous tumors.

Recapitulating physiologically relevant oxygen levels and extracellular matrix remodeling in patient-derived tumor-immune tunable models reveal targeting opportunities for immunologically cold high-grade serous tumors.

Journal: bioRxiv : the preprint server for biology

Published: July 16, 2025

Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours.

Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours.

Journal: Nature communications

Published: July 07, 2025

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.

OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.

Journal: Gynecologic oncology

Published: April 08, 2025

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 16, 2024

Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.

Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.

Journal: Journal of ovarian research

Published: May 15, 2024

Functional neuronal circuits promote disease progression in cancer.

Functional neuronal circuits promote disease progression in cancer.

Journal: Science advances

Published: May 10, 2023

Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.

Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.

Journal: Gynecologic oncology

Published: December 22, 2022

Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.

Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 09, 2021

Effectiveness of profile by Sanford behavioral weight loss program for weight loss following endometrial cancer treatment.

Effectiveness of profile by Sanford behavioral weight loss program for weight loss following endometrial cancer treatment.

Journal: Gynecologic oncology reports

Published: September 28, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026